# Charles M. Rudin

Source: https://onco.cc/people/charles-rudin/  
OnCo record `charles-rudin` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Defined the molecular subtypes of small-cell lung cancer and led early trials of DLL3-targeted therapy.

## Summary

Charles Rudin led the consensus that split small-cell lung cancer into ASCL1, NEUROD1, POU2F3 and inflamed subtypes, giving the disease its first biology-based classification. He was a lead investigator of the rovalpituzumab tesirine and tarlatamab DLL3 programmes and of KEYNOTE-604. His laboratory studies SCLC plasticity and lineage transformation of EGFR-mutant lung cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: sclc; biology; dll3
- Role: Chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
- Specialisms: Small-cell lung cancer; SCLC molecular subtypes; DLL3; Neuroendocrine carcinoma biology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Rudin%20CM%5BAuthor%5D%20small%20cell%20lung

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- targets: [DLL3](https://onco.cc/targets/dll3/)
- drugs: [Tarlatamab](https://onco.cc/drugs/tarlatamab/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [DeLLphi-304](https://onco.cc/trials/dellphi-304/)
- journals: [Nature Reviews Cancer](https://onco.cc/journals/nature-reviews-cancer/)
- key papers: [Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes](https://onco.cc/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/), [Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data](https://onco.cc/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/), [SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization](https://onco.cc/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/)

---
JSON: https://onco.cc/api/v1/entities/charles-rudin.json